undamentalytics Newsletter

Schwab Andrew J.: insider trades

Director, 10% owner at 10 companies we cover. No open-market purchases and 16 sales not made under a pre-set plan, reported from November 27, 2018 to September 24, 2026.

What happened after Schwab Andrew J.’s sales?

After their sales, the shares moved −36.3% against the index over 12 months on average (a negative figure means selling was the right call); 70% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Schwab Andrew J.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 10 −9.9% −21.4% 70% 7 −1.37 0.22 No reliable evidence
Sales, 12 months after the report 10 −36.3% −47.7% 70% 7 −2.35 0.057 No reliable evidence
Sales, 12 months after the trade 10 −35.7% −49.2% 70% 7 −2.84 0.030 Some evidence: seller right

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Skye Bioscience, Inc. SKYE —05September 13, 2024September 24, 2026
Q32 Bio Inc. QTTB —02November 27, 2018December 16, 2020
Camp4 Therapeutics Corp CAMP —02August 21, 2026August 31, 2026
Arvinas, Inc. ARVN —01July 1, 2019July 1, 2019
Ideaya Biosciences, Inc. IDYA —01November 13, 2020November 13, 2020
Cabaletta Bio, Inc. CABA —01December 14, 2020December 14, 2020
Vor Biopharma Inc. VOR —01November 18, 2021November 18, 2021
Rallybio Corp RLYB —01March 9, 2023March 9, 2023
Enliven Therapeutics, Inc. ELVN —01August 28, 2023August 28, 2023
Entrada Therapeutics, Inc. TRDA —01July 1, 2025July 1, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 24, 2026September 22, 2026 SKYE Sale $239,555 not yetnot yetnot yet
September 18, 2026September 16, 2026 SKYE Sale $64,734 not yetnot yetnot yet
August 31, 2026August 27, 2026 CAMP Sale $1,616,000 not yetnot yetnot yet
August 21, 2026August 19, 2026 CAMP Sale $879,719 not yetnot yetnot yet
August 20, 2026August 18, 2026 SKYE Sale $140,313 not yetnot yetnot yet
August 22, 2025August 21, 2025 SKYE Sale $800,548 not yetnot yetnot yet
July 1, 2025June 27, 2025 TRDA Sale $866,500 −27.2%−18.9%−16.3%
September 13, 2024September 11, 2024 SKYE Sale $1,750,352 −49.4%−51.2%−56.6%
August 28, 2023August 24, 2023 ELVN Sale $7,040,000 −30.5%+10.8%+4.6%
March 9, 2023March 7, 2023 RLYB Sale $820,000 +37.9%−104.1%−109.1%
November 18, 2021November 16, 2021 VOR Sale $5,059,802 −27.6%−53.6%−59.5%
December 16, 2020December 14, 2020 QTTB Sale $6,125,773 −15.6%−90.1%−92.3%
December 14, 2020December 10, 2020 CABA Sale $4,395,500 −29.4%−102.5%−51.6%
November 13, 2020November 11, 2020 IDYA Sale $10,928,000 +25.3%+46.2%+41.3%
July 1, 2019June 27, 2019 ARVN Sale $17,714,700 −10.8%+44.3%+29.1%
November 27, 2018November 23, 2018 QTTB Sale $594,827 +27.7%−44.2%−46.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Schwab Andrew J. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.